The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression
Open accessAbstract
The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein. Here, we show that mTOR is targeted for ubiquitination and consequent degradation by binding to the tumor suppressor protein FBXW7. Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR. Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317
Welcker, M., & Clurman, B. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2290 · Cited by 1,084
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K., & Nakayama, K. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600217 · Cited by 808
Strohmaier, H., Spruck, C. H., Kaiser, P., Won, K.-A., Sangfelt, O., & Reed, S. I. (2001) · Nature · doi:10.1038/35095076 · Cited by 583
Inactivation of hCDC4 can cause chromosomal instability
Rajagopalan, H., Jallepalli, P. V., Rago, C., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2004) · Nature · doi:10.1038/nature02313 · Cited by 551
FBXW7/hCDC4 Is a General Tumor Suppressor in Human Cancer
Akhoondi, S., Sun, D., von der Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dofou, D., Marth, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1320 · Cited by 506
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene
Mao, J.-H., Perez-losada, J., Wu, D., DelRosario, R., Tsunematsu, R., Nakayama, K. I., Brown, K., Bryson, S., & Balmain, A. (2004) · Nature · doi:10.1038/nature03155 · Cited by 390
Self-citation
Cited by
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Targeting mTOR for cancer therapy
Hua, H., Kong, Q., Zhang, H., Wang, J., Luo, T., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 899
Hu, J. L., Wang, W., Lan, X. L., Zeng, Z. C., Liang, Y. S., Yan, Y. R., Song, F. Y., Wang, F. F., Zhu, X. H., Liao, W. J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1019-x · Cited by 773
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
FBXW7: a critical tumor suppressor of human cancers
Yeh, C.-H., Bellon, M., & Nicot, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0857-2 · Cited by 515
The role of ubiquitination and deubiquitination in cancer metabolism
Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 508
Ubiquitin ligases in oncogenic transformation and cancer therapy
Senft, D., Qi, J., & Ronai, Z. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.105 · Cited by 489
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Ustun, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 356
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients
Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., Li, J., Mills, G. B., Shu, Y., Li, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.001 · Cited by 331
mTOR and the control of whole body metabolism
Polak, P., & Hall, M. N. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.024 · Cited by 306
Zhao, Y., Xiong, X., & Sun, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.029 · Cited by 272
K63 Polyubiquitination and Activation of mTOR by the p62-TRAF6 Complex in Nutrient-Activated Cells
Linares, J. F., Duran, A., Yajima, T., Pasparakis, M., Moscat, J., & Diaz-Meco, M. T. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.06.020 · Cited by 256
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Soucy, T. A., Smith, P. G., & Rolfe, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0343 · Cited by 222
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy
Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., & Brownell, J. E. (2010) · Genes & Cancer · doi:10.1177/1947601910382898 · Cited by 225
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171
“221 FBXW2, another F-box protein of CRL1, was recently found to promote ubiquitylation and degradation of MSX2 (muscle segment homeobox 2), a transcription repressor that down-regulates SOX2, leading to de-repression of SOX2 expression, and eventually promote breast cancer stem cell property.”
BackgroundREDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase
Katiyar, S., Liu, E., Knutzen, C. A., Lang, E. S., Lombardo, C. R., Sankar, S., Toth, J. I., Petroski, M. D., Ronai, Z., & Chiang, G. G. (2009) · The EMBO Reports · doi:10.1038/embor.2009.93 · Cited by 150
Chaste, P., Klei, L., Sanders, S. J., Hus, V., Murtha, M. T., Lowe, J. K., Willsey, A. J., Moreno-De-Luca, D., Yu, T. W., Fombonne, E., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.017 · Cited by 144
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway
Arabi, A., Ullah, K., Branca, R. M. M., Johansson, J., Bandarra, D., Haneklaus, M., Fu, J., Ariës, I., Nilsson, P., Den Boer, M. L., et al. (2012) · Nature Communications · doi:10.1038/ncomms1975 · Cited by 90
Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia
Cassavaugh, J. M., Hale, S. A., Wellman, T. L., Howe, A. K., Wong, C., & Lounsbury, K. M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23321 · Cited by 88
Wang, J., Wang, H., Peters, M., Ding, N., Ribback, S., Utpatel, K., Cigliano, A., Dombrowski, F., Xu, M., Chen, X., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.027 · Cited by 87
Wang, Y., Liu, Y., Lu, J., Zhang, P., Wang, Y., Xu, Y., Wang, Z., Mao, J.-H., & Wei, G. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.077 · Cited by 69
Self-citationLochab, S., Pal, P., Kapoor, I., Kanaujiya, J. K., Sanyal, S., Behre, G., & Trivedi, A. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.018 · Cited by 35
Parkin ubiquitinates mTOR to regulate mTORC1 activity under mitochondrial stress
Park, D., Lee, M. N., Jeong, H., Koh, A., Yang, Y. R., Suh, P.-G., & Ryu, S. H. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.06.010 · Cited by 25
Metadata
- Authors
- Mao, J.-H., Kim, I.-J., Wu, D., Climent, J., Kang, H. C., DelRosario, R., & Balmain, A.
- Venue
- Science
- Published
- 2008-09-12
- Volume
- 321
- Issue
- 5895
- Pages
- 1499-1502
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2015866661
- Cited by
- 424
- References
- 18
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.